Quest Diagnostics Incorporated (DGX) — 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. Although the request refers to 2011 Q4, this filing reports full-year results; selected fourth-quarter figures are included below. Amounts are U.S. dollars.
Business context
Quest Diagnostics is a large diagnostic testing and services provider. It processed approximately 146 million test requisitions in 2011. Clinical testing generated about 91% of revenue; other operations include life-insurance risk assessment, clinical trials testing, healthcare IT and diagnostic products. Athena Diagnostics and Celera were acquired during 2011.
Key financial metrics and comparison
| Metric | 2011 | 2010 |
|---|---|---|
| Net revenue | $7.510 billion | $7.369 billion |
| Operating income / margin | $995 million / 13.2% | $1.296 billion / 17.6% |
| Income from continuing operations | $507 million | $759 million |
| Net income attributable to Quest | $471 million | $721 million |
| Diluted EPS | $2.92 | $4.05 |
| Cash from operating activities | $895 million | $1.118 billion |
| Capital expenditures | $162 million | $205 million |
| Cash and cash equivalents, year-end | $165 million | $449 million |
| Total debt, year-end | $4.025 billion | $2.990 billion |
Revenue increased 1.9%, with Athena and Celera acquisitions contributing 2.2 percentage points to consolidated growth. Clinical testing requisition volume was essentially flat; revenue per requisition rose 1.1%. Operating income fell 23.2%, continuing-operations income fell 34.7%, and diluted EPS fell 27.8%. Operating cash flow less capital expenditures was approximately $734 million, versus $913 million in 2010.
Current assets were $1.401 billion against current liabilities of $1.561 billion at year-end (current ratio approximately 0.90). The company reported $1.2 billion of available capacity under credit facilities and stated that cash, operating cash flow and borrowing capacity should support operations and obligations. The term loan due May 2012 required $560 million of principal repayments during 2012.
Fourth-quarter 2011: Revenue was $1.879 billion versus $1.824 billion in Q4 2010. Income from continuing operations was $199 million versus $175 million; diluted EPS was $1.19 versus $0.97.
Material changes and unusual items
- The 2011 results included a $236 million pre-tax charge related to the California Medi-Cal lawsuit settlement. The company paid $241 million in 2011; it denied liability.
- Other 2011 items included $52 million of restructuring and integration charges, $20 million of acquisition transaction and financing costs, and $5.6 million of CEO-succession-related charges. Severe weather was estimated to reduce operating income by $18.5 million.
- Excluding these identified items, management said underlying operating performance still declined, citing lower revenue before acquisitions, higher employee compensation and benefit costs, and investment in sales and service capabilities.
- Athena was acquired for $740 million; Celera’s purchase consideration was approximately $670 million gross, with cash and short-term securities acquired. The acquisitions increased goodwill and intangible assets. Celera tax attributes were expected to reduce future tax payments by approximately $110 million.
- 2011 operating cash flow included $320 million of payments for the California settlement, restructuring/integration and acquisition costs ($202 million net of an associated reduction in estimated tax payments). Management said adjusted underlying operating cash flow approximated 2010.
- The company repurchased $935 million of shares in 2011 and increased its quarterly dividend from $0.10 to $0.17 per share, effective with the January 2012 payment. Debt rose primarily in connection with acquisitions and share repurchases.
Outlook, risks and contingencies
- Management did not provide specific 2012 revenue or EPS guidance in the supplied filing text. It expected to use most 2012 free cash flow to reduce debt and target debt/EBITDA of 2 to 2.25 times; after reaching that leverage range, it expected to return most free cash flow through dividends and repurchases.
- The company launched a program targeting $500 million of operating cost reductions by the end of 2014. Meaningful savings were expected in 2012, with most in 2013–2014; implementation charges may be material.
- Management expected long-term industry growth, while acknowledging economic weakness, lower healthcare utilization, payer consolidation, pricing pressure, and Medicare/Medicaid reimbursement constraints. Medicare clinical laboratory reimbursement fell 1.75% in 2011; new molecular-test coding and payment levels remained uncertain.
- FDA proposals concerning laboratory-developed tests and other diagnostic products could increase compliance costs or delay test introductions. Other key risks include acquisition integration, billing and collections, IT system conversions, patient-data security, and competition from hospitals and point-of-care or home testing.
- Legal and regulatory matters included a pending appeal in a False Claims Act case, a Michigan Medicaid overbilling suit, other billing-related subpoenas and inquiries, and a U.S. Senate committee inquiry. The company was cooperating with requests; it said potential losses on other legal matters were not probable at year-end and could not be estimated. A five-year Corporate Integrity Agreement begun in 2009 remained in effect.
- General and professional liability reserves were approximately $127 million at year-end; the company was substantially self-insured for a significant portion of these exposures. It also disclosed contingent predecessor-lease obligations potentially totaling several hundred million dollars, while assessing the likelihood of payment as remote.
Important facts for investors to verify
- Whether the $500 million cost-reduction program delivers the planned savings, on schedule and without disrupting service quality.
- Organic testing volume, revenue per requisition and margins, separating acquired growth from underlying performance.
- Debt reduction against the stated 2–2.25 times debt/EBITDA target, including repayment or refinancing of 2012 maturities.
- Resolution and financial impact of the Michigan case, government inquiries, pending litigation and Corporate Integrity Agreement requirements.
- Actual reimbursement and coverage effects of Medicare fee changes, molecular-test coding, healthcare reform and potential FDA regulation of laboratory-developed tests.
- Acquisition integration, goodwill and intangible-asset assumptions, and whether expected Celera tax benefits are realized.